- Home
- FIGS vs CGEM Comparison
FIGS vs CGEM Comparison
Compare FIGS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- CGEM
- Stock Information
- Founded
- FIGS 2013
- CGEM 2016
- Country
- FIGS United States
- CGEM United States
- Employees
- FIGS N/A
- CGEM N/A
- Industry
- FIGS Apparel
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- CGEM Health Care
- Exchange
- FIGS Nasdaq
- CGEM Nasdaq
- Market Cap
- FIGS 886.9M
- CGEM 1.0B
- IPO Year
- FIGS 2021
- CGEM 2021
- Fundamental
- Price
- FIGS $6.70
- CGEM $16.34
- Analyst Decision
- FIGS Hold
- CGEM Strong Buy
- Analyst Count
- FIGS 6
- CGEM 6
- Target Price
- FIGS $5.60
- CGEM $32.00
- AVG Volume (30 Days)
- FIGS 3.1M
- CGEM 666.0K
- Earning Date
- FIGS 10-31-2024
- CGEM 11-06-2024
- Dividend Yield
- FIGS N/A
- CGEM N/A
- EPS Growth
- FIGS 13.90
- CGEM N/A
- EPS
- FIGS 0.09
- CGEM N/A
- Revenue
- FIGS $550,800,000.00
- CGEM N/A
- Revenue This Year
- FIGS $3.37
- CGEM N/A
- Revenue Next Year
- FIGS $4.38
- CGEM N/A
- P/E Ratio
- FIGS $74.08
- CGEM N/A
- Revenue Growth
- FIGS 3.56
- CGEM N/A
- 52 Week Low
- FIGS $4.30
- CGEM $7.64
- 52 Week High
- FIGS $7.98
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- FIGS 62.15
- CGEM 42.53
- Support Level
- FIGS $6.40
- CGEM $15.80
- Resistance Level
- FIGS $7.06
- CGEM $17.72
- Average True Range (ATR)
- FIGS 0.29
- CGEM 1.05
- MACD
- FIGS 0.07
- CGEM -0.11
- Stochastic Oscillator
- FIGS 77.50
- CGEM 19.15
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.